Ciclopirox topical - Valeant Pharmaceuticals International

Drug Profile

Ciclopirox topical - Valeant Pharmaceuticals International

Alternative Names: 1% ciclopirox shampoo - Valeant Pharmaceuticals International; Loprox; Loprox cream; Loprox gel; Loprox Gel; Loprox shampoo; Loprox Shampoo; Loprox topical suspension

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medicis Pharmaceutical Corporation
  • Developer Valeant Pharmaceuticals International
  • Class Antifungals; Pyridones; Small molecules
  • Mechanism of Action Cell cycle inhibitors; DNA repair inhibitors; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mycoses; Seborrhoeic dermatitis

Most Recent Events

  • 11 Dec 2012 Valeant Pharmaceuticals acquires Medicis Pharmaceutical Corporation
  • 01 Mar 2012 US FDA approves ANDA application for generic version of ciclopriox gel 0.77% for seborrhoeic dermatitis of the scalp
  • 14 Apr 2003 Data presented at the 61st Annual Meeting of the American Academy of Dermatology (AAD-2003) conference have been added to the adverse events and Skin Disorders therapeutic trials section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top